{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:24:54Z","timestamp":1770956694630,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,7,9]],"date-time":"2012-07-09T00:00:00Z","timestamp":1341792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Treatment of facial lipoatrophy of HIV\/AIDS patients is mandatory by law in Brazil due to its negative impact on their quality of life. The index for facial lipoatrophy (ILA) is used as one of the inclusion criteria for patient treatment.<\/jats:p><jats:p><jats:bold>Objectives\u2002<\/jats:bold> To define a correct diagnosis and staging of facial lipoatrophy, by employing the ILA.<\/jats:p><jats:p><jats:bold>Patients and methods\u2002<\/jats:bold> This is an observational study of a series of case reports from patients submitted to facial lipoatrophy evaluation through ILA and treated with polymethylmethacrylate (PMMA) fillers. Facial lipoatrophy was classified in grades from I to IV, corresponding to mild, moderate, severe and very severe stage, according to ILA. Response to the treatment was defined as excellent (\u226591%), good (71\u201390%), moderate (51\u201370%) and insufficient (\u226450%).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A total of 20 patients were included in this study: 18 men and two women. Median age was 49\u2003years (35\u201361) and average ILA was 9.9 (7.2\u201316.8). Ten patients presented facial lipoatrophy grade II (moderate), 5 grade III (severe) and 5 grade IV (very severe). The average volume of PMMA used was 13\u2003mL (5.5\u201322\u2003mL). All patients showed good or excellent response, with a median of 86% (74\u2013100%). The most typical adverse effect was local oedema but there were no late adverse effects.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> The ILA is an excellent method for evaluation of facial lipoatrophy and also for the assessment of the response to therapy. Facial filling with PMMA showed efficacy and safety in the treatment of facial lipoatrophy in HIV\/AIDS patients.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2012.04632.x","type":"journal-article","created":{"date-parts":[[2012,7,9]],"date-time":"2012-07-09T06:41:11Z","timestamp":1341816071000},"page":"990-996","source":"Crossref","is-referenced-by-count":10,"title":["An index for staging facial lipoatrophy and evaluation of the efficacy of the treatment with polymethylmethacrylate in HIV\/AIDS patients: a pilot study"],"prefix":"10.1111","volume":"27","author":[{"given":"M.S.","family":"Serra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.K.","family":"Oyafuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.M.","family":"Trope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.H.","family":"Munhoz Leite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ramos\u2010e\u2010Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"issue":"5","key":"e_1_2_6_3_2","first-page":"79","article-title":"The effects of polylactic acid as therapy foor lipoatrophy of the face. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; Toronto, 2000 [abstract P94]","volume":"5","author":"Amard P","year":"2000","journal-title":"Antivir Ther"},{"issue":"5","key":"e_1_2_6_4_2","first-page":"68","article-title":"Risk factors for lipodystrophy and impact on the quality of life after treatment with methacrylate. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; Toronto, 2000 [abstract P76]","volume":"5","author":"Serra M","year":"2000","journal-title":"Antivir Ther"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1258\/095646206777689116"},{"key":"e_1_2_6_6_2","first-page":"123","article-title":"Safety and efficacy of poli\u2010L\u2010lactic acid in HIV lipoatrophy and lipoatrophy of aging","volume":"6","author":"Hanke CW","year":"2007","journal-title":"J Drugs in Dermatol"},{"key":"e_1_2_6_7_2","first-page":"226","article-title":"Biopol\u00edmero polialquilamida (Bio\u2010Alcamid TM), material de relleno de alto volumen para la reconstrucci\u00f3n facial en pacientes con lipoatrofia asociada a VIH Presentaci\u00f3n de 100 casos","volume":"2","author":"Casavantes LC","year":"2004","journal-title":"Dermatolog\u00eda CMQ"},{"key":"e_1_2_6_8_2","unstructured":"SerraM.Facial implants with polymethylmethacrylate (PMMA) for lipodystrophy correction: 36\u2003months follow up. XIV International AIDS Conference. [Abstract ThPeB 7378] Barcelona Jul 2002."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200502000-00005"},{"key":"e_1_2_6_10_2","unstructured":"SerraMS OyafusoLK TropeBM.Polymethylmethacrylate (PMMA) for facial atrophy treatment: 5\u2003years follow\u2010up. Presented at the XV International AIDS Conference [abstract MoOrB1060] Bangkok Thailand July 11\u201316 2004."},{"key":"e_1_2_6_11_2","unstructured":"ArakakiD LimaJN TropeBMet\u00a0al.Characterization and quantification of the facial lipoatrophy due to HAART based on the facial lipoatrophy severity index. XV International AIDS Conference [abstract B 11932] Bangkok Thailand July 11\u201316 2004."},{"key":"e_1_2_6_12_2","unstructured":"SerraM OyafusoLKM.Lipoatrophy severity index: a quantitative score for facial atrophy to evaluate treatment with polymethylmethacrylate 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Paris Jul 2003 [Abstract 117].Antivir Ther2003;8:L78."},{"key":"e_1_2_6_13_2","unstructured":"Minist\u00e9rio da Sa\u00fade do Brasil.Programa Nacional em DST\/AIDS. Bras\u00edlia. Portaria Conjunta SAS;SVS no1 de 20 de janeiro de 2009 dispon\u00edvel emwww.aids.gov.br. Last viewed April 30 2010."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4725.2002.02099.x"},{"key":"e_1_2_6_15_2","first-page":"218","article-title":"Consideraciones cl\u00ednicas de la lipoatrofia facial asociada a infecci\u00f3n por HIV","volume":"2","author":"Casavantes LC","year":"2004","journal-title":"Dermatolog\u00eda CMQ"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2012.04632.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2012.04632.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T11:27:36Z","timestamp":1696246056000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2012.04632.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,9]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/j.1468-3083.2012.04632.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04632.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,9]]}}}